Erythropoietin responsive cardiomyogenic cells contribute to heart repair post myocardial infarction

Stem Cells

Volumn 32, Issue 9, 2014, Pages 2480-2491

  Zafiriou, Maria Patapia ^a   Noack, Claudia ^a   Unsöld, Bernhard ^a   Didie, Michael ^a   Pavlova, Elena ^a   Fischer, Henrike J ^b   Reichardt, Holger M ^b   Bergmann, Martin W ^c   El Armouche, Ali ^a,d   Zimmermann, Wolfram Hubertus ^a,e   Zelarayan, Laura Cecilia ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Epo responsive MHC expressing cells; Erythropoietin; Erythropoietin responsive myosin heavy chain expressing cells; Ischemia; Myocardial regeneration

Indexed keywords

ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; MYOSIN HEAVY CHAIN; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR TBX5; TROPONIN T; ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIAC PROGENITOR CELL; CELL POPULATION; CELL PROLIFERATION; CELL SELECTION; CONTROLLED STUDY; DRUG EFFECT; FIBROBLAST; HEART DEVELOPMENT; HEART INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; STEM CELL; TISSUE REGENERATION; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; FEMALE; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; ERYTHROPOIETIN; FEMALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; RATS; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION;

EID: 84906274919     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1741     Document Type: Article

References (35)

1. Porrello ER, Mahmoud AI, Simpson E, et al. Transient regenerative potential of the neonatal mouse heart. Science 2011; 331: 1078-1080.
2. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009; 324: 98-102.
3. Senyo SE, Steinhauser ML, Pizzimenti CL, et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature 2013; 493: 433-436.
4. Hsieh PC, Segers VF, Davis ME, et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med 2007; 13: 970-974.
5. Wu H, Liu X, Jaenisch R, et al. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83: 59-67.
6. Wu H, Lee SH, Gao J, et al. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999; 126: 3597-3605.
7. Suzuki N, Ohneda O, Takahashi S, et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002; 100: 2279-2288.
8. Tada H, Kagaya Y, Takeda M, et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovascula Res 2006; 71: 466-477.
9. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999-1007.
10. Brunner S, Winogradow J, Huber BC, et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis. FASEB J 2009; 23: 351-361.
11. Prunier F, Pfister O, Hadri L, et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2007; 292: H522-H529.
12. Ott I, Schulz S, Mehilli J, et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, double-blind trial. Circ Cardiovasc Interv 2010; 3: 408-413.
13. Voors AA, Belonje AM, Zijlstra F, et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010; 31: 2593-2600.
14. Schmittgen TD, Livak KJ,. Analyzing real-time PCR data by the comparative C(T) method. Nat Protocol 2008; 3: 1101-1108.
15. Zafiriou MP, Zelarayan LC, Noack C, et al. Hepoxilin A(3) protects beta-cells from apoptosis in contrast to its precursor, 12- hydroperoxyeicosatetraenoic acid. Biochim Biophys 2011; 1811: 361-369.
16. Lee R, Kertesz N, Joseph SB, et al. Erythropoietin (Epo) and EpoR expression and 2 waves of erythropoiesis. Blood 2001; 98: 1408-1415.
17. Oh H, Bradfute SB, Gallardo TD, et al. Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A 2003; 100: 12313-12318.
18. Noack C, Zafiriou MP, Schaeffer HJ, et al. Krueppel-like factor 15 regulates Wnt/beta-catenin transcription and controls cardiac progenitor cell fate in the postnatal heart. EMBO Mol Med 2012; 4: 992-1007.
19. Rubart M, Pasumarthi KB, Nakajima H, et al. Physiological coupling of donor and host cardiomyocytes after cellular transplantation. Circ Res 2003; 92: 1217-1224.
20. Lodygin D, Odoardi F, Schlager C, et al. A combination of fluorescent NFAT and H2B sensors uncovers dynamics of T cell activation in real time during CNS autoimmunity. Nat Med 2013; 19: 784-790.
21. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: A randomized controlled trial. JAMA 2011; 305: 1863-1872.
22. Liu C, Shen K, Liu Z, et al. Regulated human erythropoietin receptor expression in mouse brain. J Biol Chem 1997; 272: 32395-32400.
23. Tsai PT, Ohab JJ, Kertesz N, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 2006; 26: 1269-1274.
24. Wickrema A, Krantz SB, Winkelmann JC, et al. Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood 1992; 80: 1940-1949.
25. Hoch M, Fischer P, Stapel B, et al. Erythropoietin preserves the endothelial differentiation capacity of cardiac progenitor cells and reduces heart failure during anticancer therapies. Cell Stem Cell 2011; 9: 131-143.
26. Zaruba MM, Soonpaa M, Reuter S, et al. Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts. Circulation 2010; 121: 1992-2000.
27. Bouscary D, Pene F, Claessens YE, et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 2003; 101: 3436-3443.
28. Prade-Houdellier N, Frebet E, Demur C, et al. Human telomerase is regulated by erythropoietin and transforming growth factor-beta in human erythroid progenitor cells. Leukemia 2007; 21: 2304-2310.
29. Wang Y, Yao M, Zhou C, et al. Erythropoietin promotes spinal cord-derived neural progenitor cell proliferation by regulating cell cycle. Neuroscience 2010; 167: 750-757.
30. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 2003; 100: 4802-4806.
31. Taniguchi N, Nakamura T, Sawada T, et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): A pilot, randomized, placebo-controlled study. Circ J 2010; 74: 2365-2371.
32. Bergmann MW, Haufe S, von Knobelsdorff-Brenkenhoff F, et al. A pilot study of chronic, low-dose epoetin-{beta} following percutaneous coronary intervention suggests safety, feasibility, and efficacy in patients with symptomatic ischaemic heart failure. Eur J Heart Fail 2011; 13: 560-568.
33. Gabel R, Klopsch C, Furlani D, et al. Single high-dose intramyocardial administration of erythropoietin promotes early intracardiac proliferation, proves safety and restores cardiac performance after myocardial infarction in rats. Interact Cardiovasc Thorac Surg 2009; 9: 20-25; discussion 25.
34. Brade T, Kumar S, Cunningham TJ, et al. Retinoic acid stimulates myocardial expansion by induction of hepatic erythropoietin which activates epicardial Igf2. Development 2011; 138: 139-148.
35. Gnecchi M, He H, Liang OD, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11: 367-368.